毒药出自中国? 探索无细胞蛋白质生产的潜力,用于毒素生物发现
Anne Paas1,2, Josephine Dresler1,2, Lea Talmann3
1Branch for Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Ohlebergsweg 12, 35392 Gießen, Germany.
International journal of molecular sciences
|August 10, 2024
概括
无细胞蛋白质生产在产生毒毒素方面表现出有限的成功,阻碍了生物发现. 有效的毒素研究和应用需要专门的无细胞系统.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 毒素含有强大的生物分子,在生物医学,农业和工业中具有显著的翻译潜力.
- 传统的以活动为导向的生物发现受到许多有毒动物产生的小毒液产量的挑战.
- 无细胞蛋白质生产为生产没有转基因生物体的生物分子提供了潜在的高速替代方案.
研究的目的:
- 为了研究一种基于 prokaryote 的无细胞系统在产生各种毒毒素的有效性.
- 评估无细胞系统在加速毒素生物发现管道中的潜力.
- 确定在毒药研究中使用无细胞技术的局限性和要求.
主要方法:
- 从不同的来源生物体中表达各种毒毒素,使用基于 prokaryote 的无细胞系统.
- 对毒素表达水平的分析和折叠能力的评估.
- 评估当前无细胞系统对于毒素生物发现的适用性.
主要成果:
- 只有有限数量的毒素能够在少量中成功表达.
- 在实现表达毒素的正确蛋白质折叠方面观察到重大挑战.
- 目前的无细胞系统在生产广泛的毒素成分方面表现出低效率.
结论:
- 在目前的形式中,基于核细胞的无细胞系统尚未有效用于广泛的毒素生物发现.
- 需要进一步开发针对毒素量身定制的无细胞系统,以克服表达和折叠的限制.
- 需要专门的无细胞技术来释放各种应用中毒成分的全部潜力.
更多相关视频
10:25Extraction of Venom and Venom Gland Microdissections from Spiders for Proteomic and Transcriptomic Analyses
Published on: November 3, 2014
33.5K
12:12Identification of Hemolytic and Phospholipase Activity in Crude Extracts from Sea Anemones by Straightforward Bioassays
Published on: March 29, 2022
2.8K
相关概念视频
01:27Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...